Press Releases
Mar 21, 2023

Data shows investigational zolbetuximab plus CAPOX reduced risk of progression or death by 31.3% vs CAPOX alone Study evaluated patients with Claudin 18.2-positive, HER2-negative, locally advanced...

Mar 16, 2023

Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK and TOKYO, March 16, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503,...

Mar 13, 2023

Treatment with fezolinetant resulted in statistically significant reductions in the frequency and severity of VMS and improvements in quality of life TOKYO, March 13, 2023 /PRNewswire/ -- Astellas...


Sep 20, 2022

Astellas was recently ranked in Seramount’s 2022 list of 100 Best Companies and Best Companies for Dads highlighting our commitment to creating a workplace where working parents are valued and...

Sep 20, 2022

Astellas ranked again in Seramount’s 2022 “100 Best Companies” list and Best Companies for Dads

Sep 13, 2022

C3 Prize Winner Shares How Her Father’s Experience with Cancer Inspired Her to Create New Patient App Astellas Pharma senior vice president and global head of Patient Centricity Dr. Anthony...


Stay Connected

Get only the email alerts you want.


Media Contacts


For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.


Astellas on Twitter
Download Fact Sheet
Explore U.S. Products